Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare Conference 2024Wednesday ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Madrigal Pharmaceuticals' Rezdiffra for NASH shows strong early demand, positioning the company as a market leader. Read why ...

Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Madrigal Pharmaceuticals continues to focus on addressing the unmet medical needs in NASH/MASH treatment and aims to enhance patient outcomes with its pioneering therapies. The company anticipates ...

Investors with a lot of money to spend have taken a bullish stance on Madrigal Pharmaceuticals MDGL. And retail traders should know. We noticed this today when the positions showed up on publicly ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) saw unusually-high trading volume on Friday following a better than expected earnings announcement.Approximately 560,141 shares ...